Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,922 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Infections (RTI) Clear all
Completed No phase listed Observational

Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset

NCT04729075
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
ARDS and COVID19 treatments
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients

NCT00354965
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
amoxicillin/clavulanate potassium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 16 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Little Rock, Arkansas • Huntington Beach, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 11, 2026, 7:32 AM EDT
Withdrawn Not applicable Interventional

Probiotic Use in Patients With Prior COPD Exacerbation

NCT02185092
View directory record Official record
Conditions
COPD, Obstructive Lung Disease
Interventions
Lactobacillus GG, Sugar pill
Dietary Supplement · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Not applicable Interventional

The Effects of Cold Liquids on the Swallowing Mechanism in Preterm Infants

NCT01863264
View directory record Official record
Conditions
Dysphagia
Interventions
Cold Thin Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 43 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 11, 2026, 7:32 AM EDT
Not listed No phase listed Observational

The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey

NCT05312619
View directory record Official record
Conditions
COVID-19, Lyme Disease, COVID-19 Vaccine
Interventions
Cross sectional survey
Other
Lead sponsor
Dr. Daniel Cameron & Associates
Other
Eligibility
12 Years and older
Enrollment
2,000 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Mount Kisco, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2013/2017 H7N9 Prime-Boost Interval

NCT03589807
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 11, 2026, 7:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flucelvax (TIVc or QIVc) Pregnancy Registry

NCT03438487
View directory record Official record
Conditions
Influenza, Human, Pregnancy, Birth Defect
Interventions
Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
Female only
Enrollment
692 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 11, 2026, 7:32 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

NCT04358211
View directory record Official record
Conditions
COVID-19
Interventions
Biological: COVID-19 convalescent plasma
Biological
Lead sponsor
Nakhle Saba, MD
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

NCT01204671
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Chandler, Arizona • Miami, Florida • Newton, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

New Reusable Mask Design With Superior Filtration and Fit

NCT04826809
View directory record Official record
Conditions
Covid19, Tuberculosis, Respiratory Viral Infection
Interventions
N95 mask, Nordell single E-100 layer mask, Nordell double E-100 layer mask
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Mankato, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

NCT01246999
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
Biological
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 9 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 11, 2026, 7:32 AM EDT
Completed No phase listed Observational

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

NCT05256316
View directory record Official record
Conditions
COVID-19
Interventions
Previously admitted COVID-19 patients in intensive care units
Other
Lead sponsor
The University of Queensland
Other
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

NCT04424316
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 49 Years · Female only
Enrollment
14,727 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
363
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 11, 2026, 7:32 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age

NCT03020472
View directory record Official record
Conditions
Influenza
Interventions
2008-2009 FluMist LAIV (Intranasal)
Biological
Lead sponsor
Stanford University
Other
Eligibility
24 Months to 35 Months
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

NCT00867139
View directory record Official record
Conditions
Influenza
Interventions
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

NCT05137236
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • Hollywood, Florida • Sunrise, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811
View directory record Official record
Conditions
Influenza Infection
Interventions
VAX102 [Flagellin.HuM2e], Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Lenexa, Kansas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 11, 2026, 7:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Influenza Human Challenge Model

NCT05332899
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Type A H3N2 Challenge
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 11, 2026, 7:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

NCT04708236
View directory record Official record
Conditions
COVID-19
Interventions
ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose, Vehicle control
Drug · Other
Lead sponsor
Oryn Therapeutics, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Results available

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

NCT02787044
View directory record Official record
Conditions
Heart Failure, Myocardial Infarction
Interventions
High Dose Trivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 93 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Patients With COVID-19

NCT04385199
View directory record Official record
Conditions
Coronavirus Infection, Coronavirus, COVID
Interventions
Convalescent plasma
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 11, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

NCT04625972
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
50
States / cities
Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 11, 2026, 7:32 AM EDT
Suspended Phase 2 Interventional

Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

NCT05387239
View directory record Official record
Conditions
Pulmonary Fibrosis, COVID-19 Respiratory Infection
Interventions
VL-PX10 and VL-P22 plus standard care, Placebo
Drug
Lead sponsor
Vitti Labs, LLC
Industry
Eligibility
25 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Liberty, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 11, 2026, 7:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

NCT00585364
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 11, 2026, 7:32 AM EDT